In the latest post on the IVI-sponsored Health Affairs blog series, Rachel Sachs provides an overview of the House of Representative's latest draft of the FDA user fee authorization bill. Sachs also examines changes in the bill from the earlier Senate markup, including incorporation of provisions from the bipartisan RACE Act and provides a possible timeline for when the bill may be voted upon.
About the Health Affairs/IVI Blog Series: Drugs and Medical Innovation
In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.